PET with FDDNP detects plaque in patients with Down syndrome

06/13/2011 | EurekAlert!

PET using the FDDNP chemical marker revealed higher binding levels of amyloid plaques and neurofibrillary tangles in patients with Down syndrome in all brain areas when compared with healthy subjects, according to a study published in the Archives of Neurology. Patients with Down syndrome also showed higher binding levels in the parietal and frontal regions, which influence cognitive function, compared with patients with Alzheimer's disease. "Neuroimaging may be a helpful tool in assessing and tracking plaque and tangle development over time in this population," senior study author Dr. Gary Small said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC